IRIS
CARLO STELLA, CARMELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.749
AS - Asia 2.164
EU - Europa 1.450
SA - Sud America 670
AF - Africa 251
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 7
Totale 12.298
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.631
SG - Singapore 1.357
BR - Brasile 600
CN - Cina 537
FI - Finlandia 366
IE - Irlanda 251
DE - Germania 215
NG - Nigeria 205
FR - Francia 124
IT - Italia 113
GB - Regno Unito 89
CA - Canada 82
NL - Olanda 74
HK - Hong Kong 53
RU - Federazione Russa 38
TR - Turchia 35
SE - Svezia 34
CZ - Repubblica Ceca 30
IL - Israele 25
BD - Bangladesh 24
IN - India 23
BE - Belgio 21
IQ - Iraq 20
AR - Argentina 19
MX - Messico 18
EC - Ecuador 14
LT - Lituania 14
AT - Austria 13
CL - Cile 13
UZ - Uzbekistan 13
ES - Italia 12
UA - Ucraina 12
VN - Vietnam 12
MA - Marocco 11
PL - Polonia 11
EG - Egitto 9
IR - Iran 8
A2 - ???statistics.table.value.countryCode.A2??? 7
CO - Colombia 7
JP - Giappone 7
KE - Kenya 7
RO - Romania 7
SA - Arabia Saudita 7
ZA - Sudafrica 7
VE - Venezuela 6
AU - Australia 5
DK - Danimarca 5
JM - Giamaica 5
NP - Nepal 5
PK - Pakistan 5
TN - Tunisia 5
JO - Giordania 4
PE - Perù 4
PY - Paraguay 4
TT - Trinidad e Tobago 4
AM - Armenia 3
AZ - Azerbaigian 3
CH - Svizzera 3
DO - Repubblica Dominicana 3
GR - Grecia 3
ID - Indonesia 3
BG - Bulgaria 2
BY - Bielorussia 2
CR - Costa Rica 2
GA - Gabon 2
GE - Georgia 2
HR - Croazia 2
KH - Cambogia 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PH - Filippine 2
SN - Senegal 2
TH - Thailandia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
CI - Costa d'Avorio 1
DZ - Algeria 1
ET - Etiopia 1
GD - Grenada 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
KR - Corea 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
MT - Malta 1
MY - Malesia 1
PS - Palestinian Territory 1
SI - Slovenia 1
Totale 12.298
Salva come PNG Salva come JPEG
Città #
Wilmington 1.310
Chandler 1.266
The Dalles 669
Singapore 645
San Mateo 502
Shanghai 474
Helsinki 360
Ann Arbor 332
Dublin 250
Leawood 243
Boardman 232
Lawrence 225
Princeton 225
Benin City 205
Ashburn 147
Fairfield 124
New York 124
Paris 112
Woodbridge 95
Amsterdam 71
Columbus 63
Toronto 58
London 54
Hong Kong 51
Seattle 47
São Paulo 43
Los Angeles 37
Milan 33
San Diego 31
Munich 28
Norwalk 27
Falls Church 26
Brno 23
Santa Clara 23
Brussels 21
Council Bluffs 21
Phoenix 20
Naples 19
Rio de Janeiro 19
Belo Horizonte 16
Kocaeli 15
Brasília 13
Monmouth Junction 13
Tashkent 13
Curitiba 12
Gunzenhausen 12
Moscow 12
Brooklyn 11
Campinas 11
Nuremberg 11
Pune 10
Redmond 10
Vienna 10
Abbiategrasso 9
Dallas 9
Houston 9
San Francisco 8
Warsaw 8
Chicago 7
Montreal 7
Porto Alegre 7
Andover 6
Atlanta 6
Boston 6
Caxias do Sul 6
Dhaka 6
Guarulhos 6
Newark 6
Redwood City 6
Sorocaba 6
Ankara 5
Beijing 5
Berlin 5
Clearwater 5
Des Moines 5
Falkenstein 5
Hanover 5
Maceió 5
Munro 5
Novokuznetsk 5
Olomouc 5
Quito 5
Recife 5
Reston 5
Stockholm 5
Amman 4
Aracaju 4
Baghdad 4
Buenos Aires 4
Buffalo 4
Cambridge 4
Caruaru 4
Charlotte 4
Frankfurt am Main 4
Goiânia 4
Guayaquil 4
Hangzhou 4
Istanbul 4
João Pessoa 4
Las Vegas 4
Totale 8.677
Salva come PNG Salva come JPEG
Nome #
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis 150
Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone (rhGH) 89
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma 85
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®) 85
Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation 84
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K delta/gamma Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 82
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 81
ACQUIRED CYCLIC THROMBOCYTOPENIATHROMBOCYTOSIS WITH PERIODIC DEFECT OF PLATELET-FUNCTION 79
Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy 76
A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogenic stem call transplantation from a HLA identical sibling 76
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma 75
Cell therapy: achievements and perspectives 73
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments 72
D Quantification of Tumor Vasculature in Lymphoma Xenografts in NOD/SCID Mice Allows to Detect Differences among Vascular-Targeted Therapies 72
Detection of maternal progenitor cells in human umbilical cord blood by single-colony karyotyping 71
Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade? 71
Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction 71
Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis 69
Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome 69
T-lymphocyte function after retroviral-mediated thymidine kinase gene transfer and G418 selection 68
AUTOLOGOUS TRANSPLANT FOR CHRONIC MYELOGENOUS LEUKEMIA USING MARROW TREATED EX-VIVO WITH MAFOSFAMIDE 67
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes 67
Amifostine (WR-2721) selective protection against melphalan genotoxicity 67
Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas 67
Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-a: evidence for a tyrosine-kinase-dependent process 66
Radioimmunotherapy and secondary leukemia : a case report 66
AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA 65
INVITRO MEGAKARYOCYTOPOIESIS IN PATIENTS WITH HIV-RELATED THROMBOCYTOPENIC PURPURA 65
EFFECT OF RECOMBINANT GAMMA-INTERFERON ON THE PROLIFERATIVE ACTIVITY OF CULTURED LEUKEMIC-CELLS 63
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide 63
UMBILICAL-CORD BLOOD AS A SOURCE OF HEMATOPOIETIC STEM-CELLS - FROM RESEARCH TO CLINIC 62
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation 62
Primary refractory and early-relapsed Hodgkin's lymphoma : strategies for therapeutic targeting based on the tumour microenvironment 62
EFFECT OF RECOMBINANT INTERFERON-ALPHA AND INTERFERON-GAMMA ON HUMAN-BONE MARROW DERIVED MEGAKARYOCYTIC PROGENITOR CELLS 61
Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts 59
Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors 59
Stem cells and stem cell transplantation 59
B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY 59
New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia 58
BIOLOGICAL ASPECTS AND CLINICAL-APPLICATIONS OF LONG-TERM BONE-MARROW CULTURE - A MEETING REPORT 58
Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice 58
Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma 58
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia : evidence for premature aging of the myeloid compartment 58
Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection 58
Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells 57
Detection of minimal residual disease in hematopoietic progenitor cell harvests : lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma 57
Specific histone patterns and acetylase/deacetylase activity at the breakpoint-cluster region of the human MLL gene 57
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells 57
Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory Hodgkin Lymphoma 56
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma 56
Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells 56
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases 56
Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (mTRAIL) 56
Risk of Cancer in Inflammatory Bowel Diseases: Umbrella Review and Reanalysis of Meta-analyses 55
ESTABLISHMENT OF 2 EPSTEIN-BARR VIRUS NEGATIVE BURKITT CELL-LINES FROM A PATIENT WITH AIDS AND B-CELL LYMPHOMA 55
CD34-POSITIVE CELLS - BIOLOGY AND CLINICAL RELEVANCE 55
Tumor-derived PGD2 and NKp30 –B7H6 engagement drives an immunosuppressive ILC2-MDSC axis 55
INVITRO AND INVIVO EFFECTS OF RECOMBINANT INTERFERON GAMMA ON THE GROWTH OF HEMATOPOIETIC PROGENITOR CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME 55
Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders 55
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice 55
Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma 55
[Mesenchymal stem cells: biology and clinical applications] 55
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma : Final results of a multicenter phase II study 54
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 54
T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors. 54
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) 53
Arachidonic acid mediates interleukin-1 and tumor necrosis factor-alpha-induced activation sf the c-jun amino-terminal kinases in stromal cells 53
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant 53
Biologic and phenotypic analysis of early hematopoietic progenitor cells in umbilical cord blood 53
Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed 53
Transforming growth factor beta(3) inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis 53
OLIGODEOXYNUCLEOTIDES ANTISENSE TO C-ABL SPECIFICALLY INHIBIT ENTRY INTO S-PHASE OF CD34(+) HEMATOPOIETIC-CELLS AND THEIR DIFFERENTIATION TO GRANULOCYTE-MACROPHAGE PROGENITORS 52
In vitro growth of mobilized peripheral blood progenitor cells is significantly enhanced by stem cell factor 52
Ex vivo manipulation of hematopoietic stem cells for transplantation: The potential role of amifostine 52
Ex vivo expansion of hematopoietic cells and their clinical use 52
The novel PI3K-ò inhibitor TGR-1202 enhances brentuximab vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. 52
INTERFERONS AS BIOLOGIC MODULATORS OF HEMATOPOIETIC-CELL PROLIFERATION AND DIFFERENTIATION 52
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunological responses in indolent B-cell lymphoma patients with relapsed and measurable disease : a pilot study 52
Selective expression and constitutive phosphorylation of SHC proteins [corrected] in the CD34+ fraction of chronic myelogenous leukemias 52
Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide 52
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma 52
Stem cell manipulation: why and how performing peripheral blood progenitor cell purging 52
Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation 52
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation : results from a named patient program at four Italian centers 52
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells 51
Effects of the tyrosine kinase inhibitor AG957 and an anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells 51
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts 51
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide 51
STEM-CELLS AND STEM-CELL FACTOR(S) 51
NATURAL-KILLER-CELL REGENERATION AFTER TRANSPLANTATION WITH MAFOSFAMIDE PURGED AUTOLOGOUS BONE-MARROW 51
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts 51
RECOMBINANT GAMMA-INTERFERON INDUCES INVITRO MONOCYTIC DIFFERENTIATION OF BLAST CELLS FROM PATIENTS WITH ACUTE NONLYMPHOCYTIC LEUKEMIA AND MYELODYSPLASTIC SYNDROMES 50
Biology and clinical applications of marrow mesenchymal stem cells 50
Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Agonistic Receptors for Cancer Therapy 50
Forced Expression of RDH10 Gene Retards Growth of HepG2 Cells 50
The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide 50
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma : a single institution experience 50
The parallel between CD45 expression and extra-medullary evolution in aggressive myeloma with high serum lactate dehydrogenase 50
Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma 50
Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma 50
Totale 6.051
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.742
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.742
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.265 4 17 6 7 9 751 336 147 445 303 8 232
2021/20221.277 68 5 19 275 19 20 30 165 130 193 286 67
2022/20233.390 487 102 293 411 326 292 0 310 604 281 236 48
2023/20241.820 139 218 335 41 30 128 67 132 24 36 280 390
2024/20253.375 88 65 33 69 85 328 197 404 531 802 403 370
2025/2026412 412 0 0 0 0 0 0 0 0 0 0 0
Totale 12.539